Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quantitative Identification of Implantation Receptivity by Single Cell Transcriptome Analysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03091023
Recruitment Status : Unknown
Verified March 2017 by Carlos Simon, Igenomix.
Recruitment status was:  Active, not recruiting
First Posted : March 27, 2017
Last Update Posted : March 27, 2017
Sponsor:
Collaborator:
Stanford University
Information provided by (Responsible Party):
Carlos Simon, Igenomix

Brief Summary:
This project aims to study the endometrial transcriptome at the single cell level in both endometrial native tissue (biopsies) and endometrial fluid. Basically, the goals are: 1) To use the resolution provided by single-cell RNA-seq to deconvolute real time dynamics in endometrium transcriptome throughout the menstrual cycle from artifacts produced by known population heterogeneity, and 2) To use endometrium fluid to replace endometrium biopsies as signal source to develop a new diagnostic platform to determine the endometrium receptive state which is high resolution and minimally invasive. This study will provide an unprecedented high-resolution characterization of the endometrium cellular hierarchy via whole transcriptome analysis throughout the menstrual stages. These results will lead to a robust definition of stage-defining gene expression signatures and resolve the long-standing inconsistencies originating from bulk tissue studies. The dataset will be further explored via informatics tools to provide biological insights into the dynamics of endometrium and initiate new anchor points for functional studies.

Condition or disease Intervention/treatment Phase
Endometrial Receptivity Diagnosis Procedure: Endometrial Biopsy and endometrial fluid collection Not Applicable

Detailed Description:

Successful embryo implantations for in vitro fertilization require both healthy embryos and a receptive endometrium. The window of implantation (WOI), during which endometrium reaches receptive state, varies among individuals. Displacements of WOI have been reported to be a major cause of repeated implantation failures. However, a reliable diagnostic metric to evaluate endometrial receptive status is lacking. The propose of this study is to use single-cell RNA seq and bioinformatics tools to develop a high-resolution platform to characterize endometrium activities and to measure endometrial receptive state in a non-invasive manner.

First objective is to develop an experimental pipeline to generate high quality single-cell RNA-seq data from endometrial biopsies and endometrial fluid from healthy patients throughout the menstrual cycle at each of these stages: early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30). These tissues will be dissociated mechanically and enzymatically and subjected to microfluidic sorting, single cell transcriptome amplification and analysis. These data will provide the first transcriptome-wide single cell data various cell types of the human endometrium.

Secondly, this study look at establish algorithmic models to distinguish epithelial and stroma populations informatically, without the need to first purify populations of interest. This will enable transcriptome analysis from mixed populations of cells.

Finally evaluate the use of endometrial fluid as an alternative source for receptivity diagnosis analyzing the transcriptome profile of single cells from Endometrial fluid collected from human patients at different menstrual stages. These signatures will also be compared and correlated with signatures obtained from biopsies, which will help us better understand the biological events that lead to the occurrence of these cells in the endometrial fluid and evaluate the potential of extending their use for diagnosis of other endometrium conditions.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Non-invasive Transcriptomic Signature at the Single Cell Level in Endometrial Fluid as a Novel Diagnostic Test of Human Endometrial Receptivity
Study Start Date : March 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arm Intervention/treatment
Active Comparator: Natural cycle

Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:

Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)

Procedure: Endometrial Biopsy and endometrial fluid collection
Active Comparator: ERA in HRT cycle
Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
Procedure: Endometrial Biopsy and endometrial fluid collection



Primary Outcome Measures :
  1. Transcriptomic profile analysis of the endometrial samples by RNA sequencing. [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy women in natural cycle;
  • Normal karyotype;
  • Negative serologic tests for HIV, HBV, HCV, RPR;
  • BMI: 18 - 30 Kg/m2 (both included);
  • Women with regular menstrual cycle (3-4/28-30 days).

Exclusion Criteria:

  • Patients who had carried an intrauterine device in the previous 3 months;
  • Patients who have taken hormonal contraceptives in the previous 2 months;
  • Adnexal or uterine pathologies;
  • Polycystic ovary;
  • Any unstable disease or medical condition that could interfere with the study or put in risk the health of the patient (evaluated by the principal researcher of the research team);
  • Any illness or medical unstable condition.

Layout table for additonal information
Responsible Party: Carlos Simon, Scientific Director IGENOMIX; Gynaecologist IVI Valencia, Igenomix
ClinicalTrials.gov Identifier: NCT03091023     History of Changes
Other Study ID Numbers: 1603-IGX-016-CS
First Posted: March 27, 2017    Key Record Dates
Last Update Posted: March 27, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Carlos Simon, Igenomix:
Endometrial receptivity
Transcriptomic
Single cell
Endometrial fluid